| Today’s Big NewsJan 3, 2025 |
| By Fraiser Kansteiner Even as Novo and Lilly continue to climb, Roche looks poised to remain the top drugmaker by revenue in 2025, Evaluate analysts predict. |
|
|
|
By Nick Paul Taylor Will 2025 be better? After another tough year, the answer to that question will shape the prospects of innumerable drug candidates and the lives of people who work in biotech. Evaluate analysts made predictions in their 2025 preview—and anyone expecting a dramatic turnaround should look away now. |
By Gabrielle Masson Regeneron has scooped up Oxular, a retinal-disease-focused company based in the U.K., closing the deal at the very end of 2024. |
By Nick Paul Taylor Academics are calling for governments to act to “safeguard the independence” of patient groups that receive funding from biopharma companies. The call reflects a belief “drug companies shape and mold patient organizations over time” through financial support. |
By Conor Hale An independent review of scientific literature searched for contaminants in tampons, including not just metals but also phthalates, parabens and volatile organic compounds. |
By Fraiser Kansteiner After plugging $23 billion into its manufacturing network to meet rampant demand for Mounjaro and Zepbound, Eli Lilly is looking to wade into a lawsuit that could allow compounding pharmacies to continue churning out the popular diabetes and obesity drugs. |
By Darren Incorvaia,Zoey Becker After being acquired by clinical-stage ADC company Oqory, Vincerx ended 2024 with a workforce reduction and C-suite clear-out that will involve Ahmed Hamdy, M.D., stepping down as CEO, while remaining as chairman. |
By Zoey Becker The German drugmaker will pay the NIH $791.5 million, while the University of Pennsylvania will get up to $467 million through the royalty settlements on the Pfizer-partnered COVID-19 vaccine Comirnaty. |
By Andrea Park New year, new Veeda. The India-based CRO formerly known as Veeda Group has kicked off 2025 with a brand makeover. |
By Darren Incorvaia An investigational drug for multiple sclerosis from Io Therapeutics has restored leg mobility and myelin nerve coatings in mice, the biotech announced Dec. 23. |
Fierce podcastsDon’t miss an episode |
| This week on "The Top Line," we bring you a special conversation from earlier this month at our New York City gala, where we celebrated this year’s Fierce 50 honorees. |
|
|---|
|
|
| |
|
